Condition
Hepatic Impairment (HI)
Total Trials
4
Recruiting
1
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
P 1 (4)
Trial Status
Completed2
Active Not Recruiting1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06442436Phase 1Active Not RecruitingPrimary
A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)
NCT07324616Phase 1CompletedPrimary
A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment
NCT07715149Phase 1Recruiting
A Pharmacokinetic Study of D-2570 in Participants With Hepatic Impairment and Normal Hepatic Function
NCT06841315Phase 1Completed
A Varegacestat Hepatic Impairment Study
Showing all 4 trials